MA46778A1 - Composition intranasale comprenant de la bétahistine - Google Patents

Composition intranasale comprenant de la bétahistine

Info

Publication number
MA46778A1
MA46778A1 MA46778A MA46778A MA46778A1 MA 46778 A1 MA46778 A1 MA 46778A1 MA 46778 A MA46778 A MA 46778A MA 46778 A MA46778 A MA 46778A MA 46778 A1 MA46778 A1 MA 46778A1
Authority
MA
Morocco
Prior art keywords
betahistine
intranasal composition
intranasal
composition
otological
Prior art date
Application number
MA46778A
Other languages
English (en)
Other versions
MA46778B1 (fr
Inventor
Christopher John Wraight
Thomas Meyer
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of MA46778A1 publication Critical patent/MA46778A1/fr
Publication of MA46778B1 publication Critical patent/MA46778B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant en tant que substance active de la bétahistine ou un sel pharmaceutiquement acceptable de celle-ci, destinée à être utilisée dans le traitement de troubles otologiques ou neurologiques chez un sujet humain par application intranasale.
MA46778A 2017-02-02 2018-02-02 Composition intranasale comprenant de la bétahistine MA46778B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02
PCT/EP2018/052695 WO2018141922A1 (fr) 2017-02-02 2018-02-02 Composition intranasale comprenant de la bétahistine

Publications (2)

Publication Number Publication Date
MA46778A1 true MA46778A1 (fr) 2021-04-30
MA46778B1 MA46778B1 (fr) 2022-08-31

Family

ID=61187302

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46778A MA46778B1 (fr) 2017-02-02 2018-02-02 Composition intranasale comprenant de la bétahistine

Country Status (34)

Country Link
US (2) US10456386B2 (fr)
EP (2) EP3474850B1 (fr)
JP (3) JP2020506930A (fr)
KR (1) KR102653545B1 (fr)
CN (2) CN110418643A (fr)
AR (1) AR111699A1 (fr)
AU (1) AU2018216970B2 (fr)
BR (1) BR112019015687A2 (fr)
CA (1) CA3051725A1 (fr)
CL (1) CL2019002145A1 (fr)
CO (1) CO2019008657A2 (fr)
DK (2) DK3698791T3 (fr)
EA (1) EA201991817A1 (fr)
ES (2) ES2807798T3 (fr)
FI (1) FI3698791T3 (fr)
HR (2) HRP20231706T1 (fr)
HU (2) HUE065336T2 (fr)
IL (1) IL268353B2 (fr)
LT (2) LT3474850T (fr)
MA (1) MA46778B1 (fr)
MX (1) MX2019008961A (fr)
MY (1) MY196333A (fr)
NZ (1) NZ755931A (fr)
PH (1) PH12019501785A1 (fr)
PL (2) PL3474850T3 (fr)
PT (2) PT3474850T (fr)
RS (2) RS65099B1 (fr)
SA (1) SA519402324B1 (fr)
SG (1) SG11201906980YA (fr)
SI (2) SI3474850T1 (fr)
TN (1) TN2019000220A1 (fr)
TW (1) TWI760429B (fr)
WO (1) WO2018141922A1 (fr)
ZA (1) ZA201904955B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (fr) * 2017-03-22 2018-09-27 Franz, Lilian Ann Procéde de traitement
CN115551479A (zh) * 2020-04-14 2022-12-30 葛兰素史克消费者健康控股(美国)有限责任公司 具有保湿益处的鼻喷雾制剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (fr) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
EP1392262A1 (fr) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
PT1530965E (pt) 2003-11-11 2006-05-31 Udo Mattern Sistema de administracao de libertacao controlada de hormonas sexuais para aplicacao nasal
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
JP2007533733A (ja) 2004-04-22 2007-11-22 モル リサーチ アプリケーションズ リミテッド 食物摂取管理の方法
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
EP2457580A1 (fr) 2004-08-25 2012-05-30 The UAB Research Foundation Activateurs de l'absorption pour l'administration de médicaments
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
JP2009504767A (ja) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
WO2007076140A2 (fr) * 2005-12-23 2007-07-05 University Of Cincinnati Procedes de traitement employant des antagonistes d’histamine h3 y compris de la betahistine
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
CN101951886A (zh) * 2007-12-21 2011-01-19 先灵-普劳健康护理产品公司 增强羟甲唑啉的光稳定性
KR20130097813A (ko) * 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
PT2293794E (pt) * 2008-05-27 2013-07-10 Univ Melbourne Métodos de tratamento de mamíferos com disfunções da trompa de eustáquio
CN102216257B (zh) * 2008-10-08 2015-11-25 凯飞药业公司 Gaba偶联物及其使用方法
AU2015327762C1 (en) * 2014-10-03 2020-10-22 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
PL3474850T3 (pl) 2020-09-21
NZ755931A (en) 2022-07-29
TWI760429B (zh) 2022-04-11
LT3474850T (lt) 2020-08-10
DK3474850T3 (da) 2020-08-03
SI3474850T1 (sl) 2020-09-30
MY196333A (en) 2023-03-24
IL268353B2 (en) 2023-10-01
HUE050829T2 (hu) 2021-01-28
EP3474850A1 (fr) 2019-05-01
IL268353B1 (en) 2023-06-01
PT3474850T (pt) 2020-07-27
US20180214432A1 (en) 2018-08-02
SG11201906980YA (en) 2019-08-27
SA519402324B1 (ar) 2023-03-16
JP2020506930A (ja) 2020-03-05
EP3698791B1 (fr) 2023-10-25
CO2019008657A2 (es) 2020-01-17
WO2018141922A1 (fr) 2018-08-09
FI3698791T3 (fi) 2024-01-11
RS60554B1 (sr) 2020-08-31
KR20190116341A (ko) 2019-10-14
MA46778B1 (fr) 2022-08-31
MX2019008961A (es) 2019-10-15
EP3474850B1 (fr) 2020-04-22
EP3698791A1 (fr) 2020-08-26
IL268353A (en) 2019-09-26
US20200022963A1 (en) 2020-01-23
DK3698791T3 (da) 2024-01-15
CN118356397A (zh) 2024-07-19
TW201831179A (zh) 2018-09-01
EA201991817A1 (ru) 2020-01-27
PH12019501785A1 (en) 2020-07-06
ZA201904955B (en) 2021-05-26
PL3698791T3 (pl) 2024-04-08
BR112019015687A2 (pt) 2020-04-28
US10456386B2 (en) 2019-10-29
HRP20231706T1 (hr) 2024-03-15
SI3698791T1 (sl) 2024-05-31
HUE065336T2 (hu) 2024-05-28
TN2019000220A1 (en) 2021-01-07
ES2807798T3 (es) 2021-02-24
CN110418643A (zh) 2019-11-05
CL2019002145A1 (es) 2019-11-04
PT3698791T (pt) 2024-01-12
LT3698791T (lt) 2024-02-12
AU2018216970A1 (en) 2019-08-22
CA3051725A1 (fr) 2018-08-09
JP2024019731A (ja) 2024-02-09
HRP20201137T1 (hr) 2021-01-22
RS65099B1 (sr) 2024-02-29
AR111699A1 (es) 2019-08-14
KR102653545B1 (ko) 2024-04-04
JP2022051872A (ja) 2022-04-01
ES2969301T3 (es) 2024-05-17
AU2018216970B2 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
BR112019025049A2 (pt) Anéis 6- 5 fundidos como inibidores de c5a
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
BR112019025230A2 (pt) Anéis 5-5 fundidos como inibidores de c5a
BR112015019412A2 (pt) inibidores de bace1
MA39346A1 (fr) Hétérocycles substitués liés par fusion en tant que modulateurs gpr119 pour le traitement du diabète, de l'obésité, de la dyslipidémie et de troubles associés
MA50406B1 (fr) Inhibiteurs pyrazole de magl
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
MX2020009235A (es) Formulacion oftalmica.
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
EA202190316A1 (ru) Конденсированное производное лактама
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
CL2017002229A1 (es) Inhibidores de bace1.
PH12021550055A1 (en) Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA202190317A1 (ru) Лекарственный препарат для наружного применения